

## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010

## **HUMAN CCL17 (C-6HIS) PROTEIN**

目录: 12064

产品名称: Human CCL17 (C-6His) Protein

规格: 10 μg, 50 μg and 100 μg

基因符号: ABCD-2;CC chemokine TARC;C-C motif chemokine

17;CCL17;chemokine (C-C motif) ligand

17;MGC138273;SCYA17MGC138271;small inducible cytokine subfamily A (Cys-Cys);member 17;Small-inducible cytokine A17;T cell-directed CC chemokine;TARC;TARCA-152E5.3;Thymus and activation-regulated chemokine

Target: CCL17

**UNIPROT ID:** Q92583

描述: Recombinant Human C-C Motif Chemokine 17 is produced by our Mammalian expression system and the target gene encoding Ala24-Ser94 is expressed with a 6His tag at the C-terminus.

背景: C-C motif chemokine 17 (CCL17) is a novel CC chemokine, it belongs to the intercrine beta (chemokine CC) family. CCL17 is expressed at high levels in thymus, and at a lower level in lung, colon, and small intestine. CCL17 is also transiently expressed in stimulated peripheral blood mononuclear cells. Among CC chemokine family members, CCL17 has approximately 24 - 29% amino acid sequence identity with RANTES, MIP-1 alpha, MIP-1 beta, MCP-1, MCP-2 and MCP-3. CCL17 has been identified to be Chemotactic factor for T-lymphocytes but not monocytes or granulocytes. CCL17 plays a role in T-cell development in thymus and in trafficking and activation of mature T-cells.

Species/Host: HEK293
Molecular Weight: 9.1 KDa

Molecular Characterization: Not available

纯化:: Greater than 95% as determined by reducing SDS-PAGE.

**Formulation & Reconstitution:** Lyophilized from nanodisc solubilization buffer (20 mM Tris-HCl, 150 mM NaCl, pH 8.0). Normally 5% – 8% trehalose is added as protectants before lyophilization.

储存和运输: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.



## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010




Figure 1. Greater than 95% as determined by reducing SDS-PAGE.